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Since the introduction of aortic stent grafting to repair
abdominal aortic aneurysm (EVAR),1 much of the data
concerning this new technology has been derived from
registries rather than trials. The two most important
registries have been the UK registry for Endovascular
Treatment of Aneurysms (RETA) based in Sheffield2
and the European Collaborators on Stent-Graft Tech-
niques for Abdominal Aortic Aneurysm Repair
(EUROSTAR) registry based in Holland.3 These
registries, although voluntary, have provided import-
ant information on EVAR and data from the RETA
registry was used in the design of the UK EVAR trials
and as an audit tool to assess centres for trial entry.
The 5-year RETA registry results are published in
this issue of the European Journal of Vascular and
Endovascular Surgery.2 Nevertheless, such registry
data, especially that related to follow up, is often
incomplete and may present a biased view of the
overall performance of new technologies. It is, there-
fore, essential that data derived from these registries is
interpreted with caution and, more importantly, that
definitive clinical practice does not change until the
on-going randomised controlled clinical trails have
had an opportunity to report their data.RETA Registry
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cedures. Annual audit reports are produced on behalf
of the Vascular Society of Great Britain and Ireland and
the British Society of Interventional Radiology. The
database has been an invaluable source of data on the
performance of EVAR devices over the last 8 years, but
as with all registries suffers in that it is voluntary and
audited in an ‘open’ fashion, possibly leading to
selection bias.
The mid-term results from the RETA registry show
that at 30 days, 90.4% of aneurysms were successfully
excluded and 5.8% of patients had died. The conver-
sion rate to open repair was 3.3%, but this rate has
been falling with time (9.1% in 1996 and 0.3% in 1999).
Post-procedural complications within 30 days
occurred in 27.8% of cases and 6.1% had persistent
endoleaks. The data shows significantly more deaths
in unfit (ASA IV) patients (14.8 versus 3.3%), and a
higher mortality rate for aorto-uni-iliac devices (12.5
versus 3.3%) and in women (5.7 versus 1.9%).
Mortality in the first year was 11% (mostly cardiac
disease and malignancy) and 10% per year thereafter
up to 5 years. Most of these deaths were not graft
related, the cumulative 5-year risk of rupture being
only 2%.
Complications related to the device and aneurysm
were reported at a rate of approximately 15% per year.
These included secondary endoleaks, graft migration,
kinking, and limb occlusions. Treatment was by
further interventional radiology or surgery, with only
38% of patients surviving with no secondary inter-
vention at 5 years.EUROSTAR Registry
The EUROSTAR registry shows similar results.3Eur J Vasc Endovasc Surg 29, 560–562 (2005)
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performance across 135 centres in 18 European
countries. This registry is also voluntary, but is the
largest registry of devices in Europe with a total of
5466 cases of EVAR on record by July 2003. Results
from first generation devices were characterised by
excellent early performance, but poor durability. The
latest data from newer devices show significant
improvements in all outcome measures, most impor-
tantly durability. One hundred and eighty seven
patients have been followed up for more than 5
years. Life table analysis shows a 5-year cumulative
results as follows; survival 79.2% and freedom from all
endoleaks 71.9%, persistent endoleaks 91.4%, second-
ary intervention 76.3% and rupture 98.6%.
The main conclusions from analysis of the EURO-
STAR database are that the incidence of rupture
increases progressively with time at least up to 5
years, but that serious adverse events occur less often
with newer devices, EVAR in high-risk patients is
probably justified if they are not expected to die within
1 year from the effects of their co-morbid conditions,
and the medium-term outcome is significantly better
in patients with small aneurysms.
The above data clearly shows that open audit, in the
form of voluntary registries, is an essential tool for the
clinical evaluation of new technologies, but they do
not replace randomised controlled trials in that they
are incomplete and open to data interpretation bias.
They do provide data as to the long term performance
of EVAR, but in a ‘selected’ group of patients. Such
registry data is considered useful in the evaluation of
new technologies and organisations such as the UK
National Institute of Clinical Excellence (NICE) now
specifically recommend that, for EVAR, patients are
either entered into a registry or treated within the
confines of a randomised controlled trial.Randomised Controlled Trials
To date, registries provide the only evidence we have
as to the long term durability of EVAR, and no level 1
evidence exists to support the use of aortic stent grafts
for the repair of abdominal aortic aneurysm. Never-
theless, the uncertainty about how EVAR compares to
conventional open repair has led to the instigation of
several randomised controlled multi-centred trials.
The UK EVAR trials were initiated in 1999.4 EVAR 1
randomises suitable patients to either endovascular
stent graft repair or conventional open repair. Patients
who are unfit to undergo open repair due to significant
co-morbidity are entered into the EVAR 2 trial. This
randomises patients to either EVAR and best medicaltreatment or best medical treatment alone. Three other
randomised controlled trials have also been initiated.
These are the Dutch DREAM, the French ACE and the
American OVER trials.EVAR 1 trial 30-day results
Early results of the EVAR 1 and Dream trials were
published in 2004 and appear to support the use of
EVAR. The EVAR 1 trial5 randomised 1082 patients
over 60 years of age with an aneurysm of 5.5 cm or
greater to either open repair or EVAR. The 30-day
mortality for EVAR was 1.7% compared to 4.7% for
open repair (pZ0.007). This mortality was lower than
that reported by the RETA and EUROSTAR registries,
perhaps because the patients randomised in EVAR 1
were those deemed fit to have an open repair
compared to the registry data which includes ‘unfit’
patients treated with primary stent grafts. In addition,
the EVAR 1 trial 30-day results report that secondary
procedures were necessary in 9.8% of EVAR patients
compared to 5.8% in the open repair group. Endoleaks
needed treatment in 3.4% of EVAR patients and 10
patients required conversion to open repair
intraoperatively.DREAM trial 30-day results
The Dutch DREAM trial6 has also published its 30-day
mortality results for endovascular versus open repair.
Despite only 345 patients being randomised, repre-
senting a 12% under recruitment, operative mortality
was similar to the UK EVAR trial at 1.2% in the EVAR
group versus 4.6% in the open repair group. Never-
theless, these results did not reach significance.
Intervention for endoleak occurred in 1.2% and the
combined rate of operative mortality and severe
complication was 4.7% for the endovascular group
versus 9.8% for the open group.Conclusions
It is essential that, as for registry data, the 30-day
randomised controlled trial data are interpreted with
caution, since the long term benefit of EVAR has yet to
be proven. At the time of writing, the 30-day EVAR 1
and DREAM randomised trial data should not be used
to advocate the widespread use of EVAR over open
repair. The authors of the EVAR 1 trial conclude that
the results of 30-day mortality serve only as evidence
to continue investigating the use of EVAR and stress
the importance of obtaining the long-term data. TheEur J Vasc Endovasc Surg Vol 29, June 2005
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results indicate that EVAR is preferable over open
repair in those who are suitable despite the results not
reaching significance. This conclusion is later muted,
suggesting that further long term data are required to
determine if the early benefit is sustained in favour of
EVAR.
The EVAR 1 and 2 trials are due to report their
medium term results in June 2005. Professor Roger
Greenhalgh will present these results at an extraordi-
nary meeting of the Endovascular Forum to be held at
the Belfry, Warwickshire, England on June 16th 2005.
On the same day the Lancet will publish the scientific
paper. By this time, one third of EVAR 1 patients will
have been followed for 4 years and these results will
give us the first robust evidence of the medium term
durability of EVAR. Funding has also recently been
secured to enable this cohort of patients to be followed
up for a further 5 years. The Dutch DREAM trial
patients are also to be followed for longer and the
French ACE and American OVER trials are
continuing.
In summary, the early and mid-term registry data
appears promising for the use of EVAR. The early
EVAR 1 and Dream trial data supports the use of
EVAR in fit patients, but concerns still exist regarding
stent graft durability and the need for continued
intervention. The registries show us that newerEur J Vasc Endovasc Surg Vol 29, June 2005generation devices appear to be performing better,
but it will require the positive reporting of the mid
term data from the randomised controlled trials before
we have sufficient evidence to allow EVAR to be fully
integrated into everyday surgical practice.References
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